151309-96-5Relevant articles and documents
Olefins from biomass feedstocks: Catalytic ester decarbonylation and tandem Heck-type coupling
John, Alex,Hogan, Levi T.,Hillmyer, Marc A.,Tolman, William B.
, p. 2731 - 2733 (2015)
With the goal of avoiding the need for anhydride additives, the catalytic decarbonylation of p-nitrophenylesters of aliphatic carboxylic acids to their corresponding olefins, including commodity monomers like styrene and acrylates, has been developed. The reaction is catalyzed by palladium complexes in the absence of added ligands and is promoted by alkali/alkaline-earth metal halides. Combination of catalytic decarbonylation and Heck-type coupling with aryl esters in a single pot process demonstrates the viability of employing a carboxylic acid as a "masked olefin" in synthetic processes. This journal is
Selective Decarbonylation of Fatty Acid Esters to Linear α-Olefins
John, Alex,Dereli, Büsra,Ortunìo, Manuel A.,Johnson, Hillis E.,Hillmyer, Marc A.,Cramer, Christopher J.,Tolman, William B.
, p. 2956 - 2964 (2017/08/21)
Selective decarbonylation of p-nitrophenol esters of fatty acids to the corresponding linear α-olefins (LAOs) was achieved using palladium catalysis. After extensive ligand screening, a mixed-ligand system exploiting the trans-spanning diphosphine XantPhos and an N-heterocyclic carbene (IPr) was identified as the most effective in yielding high α-selectivity and high conversions of the ester (>98% selectivity, >90% conversion using 2.5 mol % of PdCl2 and 5 mol % of the ligands, 190 °C, 2-2.5 h). On the basis of insights from modeling at the density functional level of theory, we propose that the mixed-ligand set achieves high α-selectivity by promoting olefin dissociation from the palladium center following β-hydride elimination, which is especially facilitated both by the combined steric bias of the mixed-ligand set and by the ability of the XantPhos ligand to coordinate in both mono- and bidentate fashions.
C-GLYCOLIPIDS WITH ENHANCED TH-1 PROFILE
-
Page/Page column 35, (2008/06/13)
The invention is directed to novel synthetic C-glycolipids that selectively induce a ThI -type immune response characterized by enhanced IL- 12 secretion and increased activation of dendritic cells. The compounds of the invention are thereby useful in treating infections, cancers, cell proliferative disorders, and autoimmune diseases, both directly and as adjuvants.